RVNC News and Press, Revance Therapeutics Inc. From 01/22/21

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the release of its inaugural ESG Report, which details the company’s commitments and efforts to build strong corporate governance, and ope...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 39th Annual J.P. Morgan Healthcare Conference, a fully virtual management access conference. Preside...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated milestones for 2021. Financial Update and Key Launch Metrics: Prelimin...

Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection PR Newswire SAN DIEGO and NEWARK, Calif. , Dec. 22, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharm...

Revance Therapeutics ([[RVNC]] +6.7%) has announced positive efficacy and duration results from Phase 2 upper facial lines study, evaluating Daxibotulinumtoxin A for Injection in the combined treatment of glabellar lines, forehead lines and crow’s feet lines.The trial showed efficacy o...

- Open-label study of DaxibotulinumtoxinA for Injection in the combined treatment of glabellar lines, forehead lines and crow’s feet lines showed efficacy of none or mild wrinkle severity in at least 92 percent of subjects at Week 4 – - Median time to return to b...

Silicon Valley biotechnology innovator in aesthetics, therapeutics and financial technology Company will invest more than $10 million in Nashville operations Project will create nearly 150 jobs over five years Tennessee Gov. Bill Lee, Department of Econom...

Revance Therapeutics (RVNC) -2.8% pre-market after the Food and Drug Administration has deferred a decision on the biologics license application for DaxibotulinumtoxinA for Injection, the company's investigational treatment of moderate to severe glabeller (frown) lines.The FDA was unable to c...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has deferred a decision on the Biologics License Application (BLA) for Daxibotul...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in a fireside chat at the Piper Sandler 32nd Annual...